European Society of Cardiology

Company

Related News

Cardiovascular Risks Common With BRAF/MEK Inhibitors in Melanoma Patients

A study finds nearly half of melanoma patients receiving BRAF or MEK inhibitors develop hypertension or cardiac dysfunction. Moderate to severe cardiac issues appear within 4 weeks and only in patients with medium or higher baseline risk. Higher baseline NT-proBNP levels are associated with increased cardiac dysfunction risk.

Related Clinical Trials

NCT ID Title Status Phase
NCT07603869

Evaluation of Cardiovascular Risks Among the Participants of the EAPC Congress 2026

COMPLETED
NCT06748924

Chronic Coronary Syndrome Snapshot Study

RECRUITING
NCT06601270

SCAD : a Registry of Spontaneous Coronary Artery Dissection

RECRUITING
NCT06495177

European Survey of Cardiovascular Disease Prevention, Diabetes and Chronic Kidney Disease (EUROASPIRE VI)

RECRUITING
NCT06469814

Snapshot Study on Patients With Heart Failure

NOT_YET_RECRUITING
NCT04437901

COVIDAR - Arrhythmias in COVID-19

UNKNOWN
NCT04396418

Stroke Prevention and Rhythm Control Therapy STEEER-AF

ACTIVE_NOT_RECRUITING NA
NCT03511885

EUROASPIRE V Survey on Cardiovascular Disease Prevention and Diabetes

COMPLETED
NCT03434314

Paraplegia Prevention in Aortic Aneurysm Repair by Thoracoabdominal Staging

ACTIVE_NOT_RECRUITING NA
NCT03280368

Adherence and Coagulation Assays in Dabigatran-treated Patients With Atrial Fibrillation

COMPLETED